Purpose:
To study the
physical properties and dissolution profiles of
commercial samples of artesunate and amodiaquine
tablets.
Methods:
Fifteen generic brands of artesunate and five generic
brands of amodiaquine tablets were obtained from drug
retail outlets in Oyo and Ogun States in southwestern
Nigeria. The tablets were subjected to various
compendial tests including identification, weight
uniformity, uniformity of content, content of active
ingredient and uniformity of diameter. Additional tests
used as a basis for the assessment of the pharmaceutical
equivalence of the products include hardness,
disintegration time and dissolution rate. Data obtained
were analysed by correlation analysis, Chi-square and
ANOVA.
Results:
Thirteen generic brands of artesunate (87 %) and four
amodiaquine brands (80 %) investigated were imported.
Two brands of the imported artesunate brands were found
to contain undetectable amount of artesunate while
another 8 samples contained overages. All the
amodiaquine brands passed the assay test as stipulated
by United States Pharmacopoeia (USP) for amodiaquine
tablets while tablet disintegration time of amodiaquine
products ranged from 5.8 – 20.7 min. All but one
artesunate sample passed the disintegration test too. A
majority of the artesunate brands tested had
significantly different dissolution profiles (p < 0.05).
Four (80 %) of the amodiaquine tablet brands tested had
similar dissolution profiles and percent drug released
within 30 min (p > 0.05). One amodiaquine brand
demonstrated poor dissolution profile as it did not meet
minimum dissolution requirements within 30 min.
Conclusion:
The detection of substandard artesunate tablets and a
poorly formulated amodiaquine tablet amongst the few
sample brands studied highlights the need for increased
drug surveillance and monitoring of the qualities of
antimalarial medicines currently in use in order to
prevent widespread treatment failure.
Keywords:
Artesunate tablets; Amodiaquine tablets; Tablet
hardness; Disintegration time; Dissolution profile;
Pharmaceutical equivalence; Drug surveillance and
monitoring.